Plerixafor

Plerixafor

Clinical data
Trade names	Mozobil
Other names	JM 3100, AMD3100
AHFS/Drugs.com	Monograph
MedlinePlus	a609018
License data	US DailyMed: Plerixafor
Pregnancy category	AU: D
Routes of administration	Subcutaneous
ATC code	L03AX16 (WHO)
Legal status
Legal status	CA: ℞-only[1] US: ℞-only[2] EU: Rx-only[3] In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	Up to 58%
Metabolism	None
Elimination half-life	3–5 hours
Excretion	Kidney
Identifiers
IUPAC name 1,1’-(1,4-phenylenebismethylene)bis(1,4,8,11- tetraazacyclotetradecane)
CAS Number	110078-46-1 Y as salt: 155148-31-5 Y
PubChem CID	65015
IUPHAR/BPS	844
DrugBank	DB06809 Y
ChemSpider	58531 Y
UNII	S915P5499N as salt: OD49913540 Y
KEGG	D08971 Y
ChEBI	CHEBI:125354
ChEMBL	ChEMBL18442 Y
CompTox Dashboard (EPA)	DTXSID70869520
Chemical and physical data
Formula	C28H54N8
Molar mass	502.796 g·mol−1
3D model (JSmol)	Interactive image
SMILES N1CCNCCCN(CCNCCC1)Cc2ccc(cc2)CN3CCCNCCNCCCNCC3
InChI InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2 Y Key:YIQPUIGJQJDJOS-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Plerixafor, sold under the brand name Mozobil, is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme.